alexa PI3K Pathway Inhibition In Breast Cancer
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Conference on Translational & Personalized Medicine
August 05-07, 2013 Holiday Inn Chicago-North Shore, IL, USA

Cynthia X. Ma
Accepted Abstracts: Transl Med
DOI: 10.4172/2161-1025.S1.010
Abstract
Aberrant activation of the phosphatidylinositide 3-kinases (PI3K) pathway occurs frequently in breast cancer and contributes to treatment resistance. There has been a significant interest in developing inhibitors against components of the PI3K pathway, including PI3K, AKT and mTOR for the treatment of breast cancer. In estrogen receptor positive breast cancer, mutation in PIK3CA is the most common genetic abnormality in this tumor type and activation of the PI3K pathway has been associated with the development of acquired endocrine resistance. Everolimus, a mTOR inhibitor, has been shown to improve the efficacy of exemestane and is in clinical use for the treatment of non-steroidal aromatase inhibitor resistant estrogen receptor positive metastatic breast cancer. In triple negative breast cancer (TNBC), activation of the PI3K signaling has been attributed to the frequent loss of the negative regulators of this pathway, including PTEN and INPP4B. Laboratory and clinical trials are ongoing to establish PI3K pathway as a therapeutic target for TNBC. For HER2 positive breast cancer, inhibitors of PI3K pathway are being evaluated to overcome resistance to HER2 targeted agents. In this lecture, we will review genetic aberrations in components of this pathway in different subtypes of breast cancer, preclinical rational and the clinical development of inhibitors against this pathway.
Biography
Cynthia X. Ma obtained her M.D. in Beijing Medical University in China in 1990 and subsequently completed her Ph.D. at the University of Cincinnati in 1997 and Hematology and Oncology Fellowship from Mayo Clinic, Rochester in 2005. After graduation from her fellowship training, she was recruited by Washington University in St. Louis. She is currently an Associate Professor of Medicine and a Breast Oncologist at Washington University in St. Louis. She has published over 60 papers and is the Principal Investigator for multiple early phase clinical trials developing targeted therapeutics agents in breast cancer.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]line.com

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version